Table 2.
Report of various studies involving the use of ivermectin against RNA viruses.
| Type of study | Type of infection | Results/Remarks |
|---|---|---|
| Clinical study | SARS-CoV-2 | Significantly lower mortality[15]. |
| In vitro study (Australia) | SARS-CoV-2 | Inhibition of virus[9]. |
| observational registry-based study (169 Hospitals, 1970 patients) | COVID-19 critically ill patients | A significantly higher survival rate was observed[16]. |
| Dominician Republic based clinical study | The early stage confirmed patients with COVID-19. | 99% of the patients were recovered with 100–200 mcg/kg (initial dose) and 400 mcg/kg (final dose) (India – Trial Site News, 2020) |
| Bangladesh based clinical study (n = 60) | Symptomatic, confirmed SARS-CoV-2 infected patients | Ivermectin + doxycycline produced a better recovery rate as compared to hydroxychloroquine + azithromycin. The former combination also shortened the duration of recovery[6]. |
| A matched controlled study (AIIMS Bhubaneshwar) | Health care workers (positive and negative) | 73% reduction in COVID-19 infection was observed after two doses of ivermectin prophylaxis (300 ug/kg given at an interval of 72 h)[13]. |
| In vitro studies | Dengue virus (DENV) | Ivermectin (25–50 μM) produced an Inhibitory effect[11]. |
| In vitro studies | Hendra virus (HEV) | Ivermectin (25–50 μM) produced an inhibitory effect[8]. |
| In vitro studies | Zika virus (ZIKV) infected vero cells | Ivermectin potently inhibited the virus[12]. |
| In vitro studies | Yellow fever virus | Ivermectin produced an Inhibitory effect[8]. |
| In vitro studies | Human immunodeficiency virus type 1 | An inhibitory effect was produced[8]. |
| In vitro studies | Avian influenza A virus | Ivermectin inhibited the nuclear transmission of viral ribonucleoprotein complexes[8]. |
| In vitro studies | Chikungunya virus (CHIKV) | Ivermectin inhibited the CHIKV infection in BHK-21 cell line[8]. |